David Bonita

General Partner·OrbiMed

Bio

Professional summary

David Bonita is a General Partner at OrbiMed and has been with the firm since 2004. He previously worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. Company bios list his board service at Ikena, Acutus Medical, Prelude Therapeutics, Repare, Third Harmonic Bio, and other private companies.

Notable companies

Selected portfolio companies the partner has backed

IkenaAcutus MedicalPrelude TherapeuticsRepare TherapeuticsThird Harmonic Bio

Background

Career, education, and skills

Career history

OrbiMedGeneral Partner2004 – Present
Morgan StanleyCorporate Finance Analyst, Healthcare Investment Banking
UBSCorporate Finance Analyst, Healthcare Investment Banking

Education

Harvard UniversityA.B. in Biological Sciences
Columbia UniversityM.D./M.B.A.

Other partners at OrbiMed

12 more profiles

View firm →

Aditya Tolia

Private Equity Senior Analyst

OrbiMed

Private Equity Senior Analyst at OrbiMed with prior Investec and PwC banking experience.

Financial modelingHealthcare investingInvestment bankingM&APrivate equity

Alexis Megibow

Private Equity Associate

OrbiMed

Private Equity Associate at OrbiMed.

Healthcare investingPrivate equityVenture capital

Ankesh Bhansali

Managing Director

OrbiMed

OrbiMed Asia Managing Director focused on healthcare private equity.

Asia healthcareCapital marketsHealthcare deliveryHealthcare private equityM&APharmaceuticals

Arun Sadhanandham

Managing Director

OrbiMed

OrbiMed Asia Managing Director investing in healthcare private equity.

Asia healthcareHealthcare deliveryHealthcare private equityInvestment bankingMedical devicesPharmaceuticals

Brendan Weber, CFA

Principal

OrbiMed

Principal on OrbiMed's Credit & Royalty team focused on structured credit and royalty financings.

Healthcare creditMedical devicesPharmaceuticalsRoyalty-based financingStructured credit

Carl Gordon

Managing Partner

OrbiMed

OrbiMed Managing Partner leading private equity and biotech company formation.

BiotechnologyBoard governanceCompany formationHealthcare private equityInnovative therapeuticsLife sciences

Carl L. Gordon

Managing Partner

OrbiMed

Carl L. Gordon is a Managing Partner at OrbiMed and leads the firm's private equity team.

Life-sciences private equityTherapeuticsVenture investing

Carter Neild

Managing Partner

OrbiMed

OrbiMed Managing Partner focused on healthcare royalties and Asia private investments.

Asia private investmentsHealthcare private equityHealthcare royaltiesInvestment managementStructured healthcare finance

Clay Daniel DeMarcus

Principal

OrbiMed

Principal focused on medical technology and non-therapeutics venture investing.

Healthcare equity researchHealthcare investment bankingMedical technologyNon-therapeuticsVenture-stage investing

Cooper Steputis

Private Equity / Venture Capital

OrbiMed

Healthcare private equity and venture investor with prior investment banking experience.

Healthcare venture capitalInvestment bankingMolecular biologyNeurosciencePrivate equity

Daniel Ying

Executive Director

OrbiMed

OrbiMed Asia Executive Director focused on pharma and biotech investments.

Asia healthcareBiotechnologyChina healthcare marketHealthcare private equityPharmaceuticals

David Wang

Partner

OrbiMed

OrbiMed Asia Partner focused on Greater China healthcare investments.

BiotechnologyDiagnostic imagingGreater China healthcareHealthcare private equityMedical diagnosticsPersonalized medicine